Littlejohn Financial Services Inc. Boosts Stock Holdings in Eli Lilly and Company $LLY

Littlejohn Financial Services Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 707.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,278 shares of the company’s stock after buying an additional 2,872 shares during the period. Eli Lilly and Company accounts for 1.8% of Littlejohn Financial Services Inc.’s holdings, making the stock its 22nd biggest position. Littlejohn Financial Services Inc.’s holdings in Eli Lilly and Company were worth $2,501,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new position in Eli Lilly and Company during the second quarter worth approximately $8,827,714,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Eli Lilly and Company by 13.4% during the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after buying an additional 564,736 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan coverage highlights continued GLP‑1 sales strength and pipeline-driven momentum entering 2026, reinforcing expectations for revenue growth from obesity and next‑generation incretin candidates. JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation
• Positive Sentiment: JPMorgan also highlights commercial and governmental access efforts for Lilly’s obesity drugs — implying management focus on scaling reimbursement and market penetration, which supports longer‑term sales trajectory. JPM26: Eli Lilly’s obesity drugs target commercial and governmental access
• Positive Sentiment: Analysts continue to back LLY: Jefferies reaffirmed a Buy with a $1,300 target and BMO kept a Buy — signals that sell‑side expectations remain bullish despite near‑term noise. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: CEO David Ricks reiterated ambition and portfolio outlook (including obesity launches) in a recent interview, which supports confidence in execution and the company’s sizable market opportunity. Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
• Neutral Sentiment: Lilly’s AI collaboration mentions (e.g., with NVIDIA) position the company on the technological edge of drug discovery — positive structurally but not an immediate revenue driver. JPM: NVIDIA Launches AI Collaborations with Eli Lilly, Thermo Fisher
• Negative Sentiment: FDA reportedly delayed its decision on Lilly’s oral obesity candidate orforglipron (a priority‑voucher recipient), creating uncertainty about near‑term market timing and catalyzing a negative trader reaction. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
• Negative Sentiment: A compounding pharmacy has filed suit alleging coordinated conduct by Lilly and Novo Nordisk around GLP‑1 dominance; legal/legal‑risk headlines add regulatory and reputational uncertainty for the GLP‑1 franchise. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy

Analysts Set New Price Targets

A number of research firms recently issued reports on LLY. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Guggenheim reaffirmed a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Zacks Research raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Finally, HSBC reiterated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Five analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $1,174.70.

Eli Lilly and Company Trading Down 3.8%

Shares of LLY opened at $1,032.51 on Friday. The firm has a 50-day moving average price of $1,049.04 and a 200 day moving average price of $868.38. The firm has a market capitalization of $976.11 billion, a P/E ratio of 50.51, a P/E/G ratio of 0.78 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the company earned $1.18 EPS. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.